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Background: The non-compliant use of opioid substitution treatment (OST) medicines is widespread and
well-documented. However, less is known about characteristics of non-compliant OST medicine use and the factors
that predict it. The two main goals of this study are to compare characteristics of non-compliant levomethadone,
methadone, and buprenorphine use and to explore factors that may differentially predict it among opioid
dependent persons in treatment.
Methods: Data from 595 opioid dependent patients with non-compliant OST medicine use were analyzed.
Characteristics of use between substances were compared using chi-squared tests and predictive factors were
explored through multinomial logistic regressions.
Results: Non-compliant levomethadone and methadone use was characterized by more frequent parallel
consumption of other psychoactive substances and intravenous use, whereas buprenorphine was more often
procured without a prescription. Regarding predictive factors, methadone was perceived to relieve withdrawal
symptoms better than buprenorphine and levomethadone was perceived as being better at modulating the effects
of other substances and worst at enhancing mood.
Conclusions: Patterns of non-compliant use differ according to OST medicine. These patterns are considered with
the reduction of non-compliant use and the improvement of treatment in mind.
Keywords: Buprenorphine, Levomethadone, Methadone, Opioid substitution treatment, Non-compliant use,
Prescription drugs, Opioid maintenance therapy, Heroin dependence, Opioid dependenceBackground
Methadone maintenance treatment for opioid dependent
patients was introduced in Germany in 1988 as part of a
pilot study [1]. Since then, opioid maintenance or substi-
tution treatment (OST) has expanded to include bupre-
norphine in 2000 and diamorphine in 2009 [2] and is
considered to be widespread and well-established [1]. It
is estimated that the past-year prevalence of problem
opioid use in Germany in 2011 was between 0.12-0.34%
[3]. The German Federal Institute for Drugs and Medical
Devices (BfArM) reports that 75,400 patients under-
went OST in 2012, as recorded on census day [4]. This* Correspondence: casati@ift.de
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users find themselves in substitution treatment.
In 2011, methadone was the most commonly pres-
cribed OST medicine (54.8%), followed by levometha-
done (25.4%) and buprenorphine (19.2%). The remaining
less than one percent was made up of dihydrocodeine,
codeine, and diamorphine OST prescriptions [5]. Levo-
methadone and methadone are full opioid agonists while
buprenorphine is a partial opioid agonist with a longer
half-life. The pharmacological effectiveness of levometha-
done and methadone as OST medicines relies on the
levorotary form found in both substances. However, their
overall effects are not identical as the dextrorotary form in
racemic methadone has been found to produce additional
side effects [6]. Levomethadone is available in syrup form,td. This is an Open Access article distributed under the terms of the Creative
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as sublingual tablets for OST in Germany. OST medicines
are mainly delivered by office-based general practitioners
in conjunction with community-based pharmacies and a
smaller percentage of OST delivery occurs in specialized
addiction clinics [7]. There are no differences between the
take-home protocols of levomethadone, methadone and
buprenorphine regarding regulations for the amount of
time, prerequisites or dispensing [8]. However, take-home
methadone and levomethadone are dyed and made
thicker before being handed out so as to be more difficult
to inject [9].
Opioid dependence is characterized by persistent drug-
seeking behavior and is often accompanied by poly-drug
use and non-compliant OST medicine use. Man et al. [10]
found that 66% of opiate users who had overdosed re-
ported mixing opiates with at least one other drug, such
as alcohol (14.9%), benzodiazepines (31.1%), or others
(8.1%). Specka et al. [11] reported that 90% of opioid users
in their study also consumed at least one other psycho-
active substance. Cocaine (55%), cannabis (65%), alcohol
(60%), and benzodiazepine (53%) use were found to be the
most common. Thus, reducing patients’ consumption of
psychoactive substances (other than the appropriate con-
sumption of OST medicine) is one of the primary goals of
OST [1]. Alongside poly-drug use, OST medicines are
often used in ways other than as medically intended.
These include intravenous instead of oral or sublingual
application, snorting, buying and selling on the black mar-
ket, and doctor-shopping [12-18]. In order to prevent the
latter, BfArM keeps a registry of OST in Germany. In
2012, approximately 160 cases of double opioid substitu-
tion treatment (i.e. patient receives two or more OST
medicines from different doctors, without doctors’ know-
ledge) were identified and terminated as soon as the doub-
ling was confirmed [4]. According to the German Medical
Association, the five main goals of opioid substitution
treatment are to ensure survival, to stabilize patients’
health and treat drug related diseases, to integrate pa-
tients in social and work life, to reduce consumption of
other addictive substances, and ultimately to free patients
from opioid dependence [19].
Although the non-compliant use of OST medicines
has been extensively documented [12,13,15-18,20-22],
little research has focused on the characteristics of non-
compliant OST medicine use and the factors that predict
it. A characterization of use and predictive factors could
help increase our understanding of the phenomenon and
help guide treatment and prevention efforts. Therefore,
the two main goals of this study are to compare character-
istics of non-compliant levomethadone, methadone, and
buprenorphine use and to explore factors that may differ-
entially predict non-compliant OST medicine use among
opioid dependent persons.Regarding the first goal, the following four characteris-
tics of non-compliant use will be compared between
OST medicines: 1) parallel consumption of OST medi-
cine and other drugs 2) use of OST medicine not as
medically intended 3) intravenous use of OST medicine
and 4) procurement of OST medicine without a pre-
scription. Given the likeness in the effects that levome-
thadone and methadone produce, we hypothesize that
the above listed four characteristics of non-compliant
use will differ between buprenorphine and levometha-
done and buprenorphine and methadone but not bet-
ween levomethadone and methadone.
Our second goal is to explore predictive factors of
non-compliant levomethadone, methadone and bupre-
norphine use. We will investigate the predictive value of
age, gender, frequency of use, and reasons for use. We
hypothesize that sedation and anxiety relief will predict
non-compliant use of levomethadone and methadone.
This hypothesis is based on findings that buprenorphine
tends to produce a more “clear head” than methadone,
under which patients report a dull feeling and subdued
emotions [23,24]. With regards to the predictive effects
of age, gender, frequency of use, and other reasons for
use, no directed hypotheses can be formulated. The in-
fluence of these variables on OST medicine use will be
tested in an explorative way.
Methods
Data collection
Data from the “Phar-Mon” project collected between
January 2007 and August 2011 were used. Phar-Mon is an
early warning system that monitors medicine use among
patients of outpatient addiction treatment centers. The 34
treatment centers participating in Phar-Mon account for
approximately 5% of the outpatient institutions pertaining
to the German Addiction Treatment Statistics (DSHS).
DSHS is an ongoing monitoring system on substance
abuse treatment which includes information on diagnostic
data and socio-demographic variables of patients as well
as information on the current substance abuse treatment
situation in Germany. The sample of centers participating
in Phar-Mon was selected randomly. It is a representative
sample of the DSHS outpatient centers on the basis of
number of patients treated and proportion of opioid
dependent patients in treatment. The Phar-Mon project is
funded by the German Federal Ministry of Health. For
more extensive information on Phar-Mon and its metho-
dology, see references [25,26].
Participant recruitment took place in the outpatient
addiction treatment centers. Participation was voluntary,
based on informed consent, and not required to receive
treatment. Reporting non-compliant OST use did not
compromise continuation of treatment as patients were
not expected to be compliant upon entry. In accordance
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schungsgemeinschaft - DFG) guidelines [27], ethics ap-
proval was not necessary given that the non-experimental
design did not expose subjects to risks or high levels of
stress. Additionally, subjects were informed of the study’s
goals and procedures. Data were recorded and handled
anonymously.
The study sample was made up by opioid dependent
patients seeking treatment and who were using OST
medicines in a non-compliant manner. Opioid depend-
ence was established using ICD-10 criteria for dependence
syndrome. Opioid dependent patients were interviewed
on their consumption of OST medicines regardless of
whether they were already undergoing OST. No further
treatment data (e.g. enrollment in OST, first time seeking
treatment) were available.
Data were collected by means of the Phar-Mon ques-
tionnaire for the following variables: basic demographic
variables (i.e. main diagnosis, age, and sex), OST medi-
cine, characteristics of non-compliant OST medicine use
(i.e. parallel consumption of OST medicine and other
psychoactive drugs which undermine the purpose of OST
and jeopardize health; use not as medically intended i.e.
other than for the purposes of OST; intravenous use; and
procurement without a prescription), consumption fre-
quency, and reasons for use (i.e. to sedate, to induce eu-
phoria, to relieve anxiety, to avoid withdrawal symptoms,
to stimulate/arouse, to relieve pain, as a cognitive en-
hancer, to modulate the effects of other substances, and to
enhance/brighten mood). The questionnaire was adminis-
tered upon treatment entry by trained personnel through
face to face interviews. Multiple entries were possible for
the characteristics of non-compliant use and for reasons
for use. Reasons for use referred specifically to the indivi-
dual OST medicine consumed, not to reasons for non-
compliant use. Data on OST medicine use within the past
six months were collected.
The four characteristics of non-compliant OST medi-
cine use (see above) were selected based on the German
Federal Medical Association’s guidelines for opioid sub-
stitution treatment. These stipulate that patients in OST
shall refrain from consuming additional substances that
may interfere with the goals of substitution treatment,
that OST medicines are to be taken orally/sublingually
(with the exception of diamorphine) and not to be han-
ded down or dealt with, and that they are meant to be
administered though prescriptions by qualified personnel
[19]. Infringements on these regulations, especially when
recurrent, may result in discontinuation of OST. Given
that patients in this study were beginning treatment,
reporting non-compliant OST use did not affect treat-
ment continuation. The criteria for non-compliance were
screened on the basis of patients’ self-report. Fulfillment
of one or more of the above listed four criteria within thepast six months was sufficient to classify the case as non-
compliant.
Statistics
Statistical analyses were performed using SPSS software
(version 19). Regarding our first goal (i.e. to compare the
characteristics of non-compliant levomethadone, metha-
done, and buprenorphine use), a chi-squared analysis
was performed. Regarding our second goal (i.e. to explore
factors that may differentially predict non-compliant OST
medicine use), we conducted two multinomial logistic re-
gressions. In the first model, buprenorphine was the refer-
ence group and was compared against methadone and
levomethadone. For the comparison of methadone against
levomethadone, a second model was run with methadone
as the reference group. As predictors, age, male gender,
frequency of consumption (consumption days within past
month), and reasons for use (yes vs. no) were included in
the models. Collinearity diagnostics were conducted and
evaluated based on the variance inflation factor (VIF) and
tolerance. Values of less than 1.4 (VIF) and greater than
0.69 (tolerance) indicated no serious multicollinearity. All




A total of 595 cases of non-compliant OST medicine use
was recorded. These cases corresponded to 79 cases of
levomethadone use, 297 cases of methadone use, and 219
cases of buprenorphine use (buprenorphine alone = 212
and buprenorphine/naloxone = 7). Descriptive statistics
for age, gender, mean days of consumption, and reasons
for use for the three OST medicines can be found in
Table 1.
Comparison of the characteristics of non-compliant OST
medicine use
Figure 1 provides an overview of the characteristics of
non-compliant use for each of the three OST medicines.
Parallel consumption of OST medicines and other drugs
was significantly more often reported for levomethadone
(91.1%) and methadone (87.5%) than for buprenorphine
(65.8%) (χ2 = 44.47, df = 2, p < 0.001). The individual com-
parisons for use not as medically intended yielded a mar-
ginal difference between buprenorphine (38.7%) and
levomethadone (23.1%) that was not significant at the .05
level. Injecting the OST medicine was significantly more
common for levomethadone (21.8%) and methadone
(17.9%) than for buprenorphine (8.8%) (χ2 = 11.25, df = 2,
p < 0.005). Finally, buprenorphine (61.6%) was procured
significantly more often without a prescription than le-
vomethadone (32.9%) and methadone (35.0%) (χ2 = 41.17,
df = 2, p < 0.001).
Table 1 Descriptive statistics for the buprenorphine, levomethadone and methadone groups according to age, gender,
consumption frequency, and reasons for use
Buprenorphine (n = 219) Levomethadone (n = 79) Methadone (n = 297)
Age, M (SD) 34.41 (7.92) 37.18 (9.60) 35.13 (8.59)
Gender, % male 90.4 69.6 81.1
Consumption days within past month, M (SD) 23.27 (10.35) 28.58 (6.13) 28.00 (6.13)
Reasons for use, %
To sedate 50.9 55.7 54.9
To induce euphoria 8.9 5.1 9.1
To relieve anxiety 18.6 21.5 20.6
To avoid withdrawal symptoms 89.4 97.5 97.0
To stimulate/arouse 6.5 5.1 9.9
To relieve pain 5.1 7.6 10.2
As a cognitive enhancer 3.7 5.1 7.2
To modulate the effects of other substances 8.4 24.1 16.4
To enhance/brighten mood 35.0 19.0 30.3
Footnote: The above stated are valid percentages. The maximum number of missings in any group was n = 5.
Casati et al. Substance Abuse Treatment, Prevention, and Policy 2014, 9:19 Page 4 of 8
http://www.substanceabusepolicy.com/content/9/1/19Exploration of predictive factors for non-compliant OST
medicine use
The two multinomial logistic regression models signifi-
cantly predicted OST medicine use and accounted for
16.9% and 19.6% of the variance, respectively. Table 2
displays odds ratios and confidence intervals for each of
the predictor variables with significant results marked
with *.
Age and gender
Older age was found to be associated with an increase in
the odds of consuming levomethadone over buprenor-
phine by a factor of 1.05 (95% CI = 1.02-1.08) and levo-
methadone over methadone by a factor of 1.04 (95% CI =
1.01-1.07). Being male was associated with smaller prob-
abilities of consuming levomethadone than buprenor-
phine (OR = 0.21, 95% CI = 0.10-0.43), methadone thanFigure 1 Characteristics of non-compliant use for buprenorphine, levbuprenorphine (OR = 0.45, 95% CI = 0.25-0.80), and
levomethadone than methadone (OR = 0.47, 95% CI =
0.26-0.85).
Consumption frequency
An increase in consumption frequency was associated
with an increase in the odds of levomethadone over bu-
prenorphine consumption by a factor of 1.07 (95% CI =
1.02- 1.13) and methadone over buprenorphine consump-
tion by a factor of 1.06 (95% CI = 1.04-1.09).
Reasons for use
Avoiding withdrawal symptoms was associated with an
increase in the odds of consuming methadone instead of
buprenorphine (OR = 2.84, 95% CI = 1.23-6.58). Modulat-
ing the effects of other substances was associated with an
increase in the likelihood of consuming levomethadoneomethadone, and methadone. *Symbol denotes p < .05.







Age 1.05 (1.02-1.08)* 1.01 (0.99-1.04) 1.04 (1.01-1.07)*
Male gender 0.21 (0.10-0.43)* 0.45 (0.25-0.80)* 0.47 (0.26-0.85)*
Consumption days within past month 1.07 (1.02-1.13)* 1.06 (1.04-1.09)* 1.01 (0.96-1.06)
Reasons for use
To sedate 1.46 (0.80-2.68) 1.23 (0.81-1.87) 1.18 (0.68-2.07)
To induce euphoria 0.58 (0.16-2.09) 0.87 (0.42-1.81) 0.67 (0.20-2.23)
To relieve anxiety 0.95 (0.46-1.94) 0.85 (0.52-1.39) 1.11 (0.57-2.16)
To avoid withdrawal symptoms 2.66 (0.57-12.39) 2.84 (1.23-6.58)* 0.94 (0.19-4.58)
To stimulate/arouse 0.84 (0.20-3.46) 1.30 (0.57-3.00) 0.64 (0.17-2.38)
To relieve pain 1.05 (0.34-3.29) 1.88 (0.85-4.14) 0.56 (0.21-1.49)
As a cognitive enhancer 1.93 (0.47-7.97) 1.74 (0.68-4.47) 1.11 (0.31-3.97)
To modulate the effects of other substances 5.73 (2.42-13.55)* 1.86 (0.97-3.60) 3.08 (1.47-6.44)*
To enhance/brighten mood 0.31 (0.14-0.71)* 0.74 (0.45-1.20) 0.42 (0.19-0.92)*
Footnote: Factors that proved to be significant at the .05 level are marked with *. In the first model (first two columns), buprenorphine was the reference group.
In the second model (third column), methadone served as the reference group.
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levomethadone over methadone (OR = 3.08, 95% CI =
1.47-6.44). Finally, the consumption of an OST medicine
to enhance/brighten mood was associated with decreased
odds of consuming levomethadone than buprenorphine
(OR = 0.31, 95% CI = 0.14-0.71) and with decreased odds
of consuming levomethadone than methadone (OR = 0.42,
95% CI = 0.19-0.92). Sedating, inducing euphoria, relieving
anxiety, stimulating, relieving pain and consuming with
the purpose of cognitive enhancement were not found to
predict the type of OST medicine used.
Discussion
More cases of non-compliant methadone use were re-
ported compared to buprenorphine or levomethadone.
Although no rates can be calculated from these raw
numbers because of the missing total number of patients
treated, these findings could suggest a preference for
methadone, perhaps due to its larger prescription rates
[5]. This could support findings that non-medical pre-
scription drug use is influenced by the availability of a
drug [28,29]. However, other factors probably also play a
role in misuse, given that the high prescription rates for
levomethadone [5] do not correspond to the lower num-
bers of misuse. Moreover, the abuse potential for bupre-
norphine/naloxone combination products seems to be
lower than for buprenorphine alone [12,30]. Neverthe-
less, these are just indications and the missing rates do
not allow for further interpretations.
Regarding the characteristics of non-compliant OST
use, we were able to confirm our hypotheses for the var-
iables parallel consumption, injection, and procurement
without a prescription but not for use not as medicallyintended. We found that levomethadone and methadone
are more frequently consumed in conjunction with other
psychoactive substances. This parallel consumption may
be linked to expectations for modulating the effects of
drugs. We also found that levomethadone and metha-
done were more frequently injected than buprenorphine.
In fact, levomethadone syrup was injected almost two
and a half times more frequently than buprenorphine
sublingual tablets. This is surprising given that take-
home methadone and levomethadone syrups are thick-
ened to prevent intravenous (IV) use. While Guichard
et al. found that syrup formulations are more difficult to
inject whereas buprenorphine in tablet form can be eas-
ily injected once crushed and diluted in water [31], our
results again suggest the contrary. The precautionary
measure implemented for take-home formulations could
still reduce IV use, but it does not appear to prevent it.
Further research on the influence of medicine form on
OST compliance is needed to clarify this question.
Furthermore, our results indicate that in most cases of
non-compliant buprenorphine use, the substance was
procured without a prescription and that this occurred
significantly more often than for levomethadone and
methadone. Medicine form could also play a role here,
given that buprenorphine in tablet form can be more
easily smuggled out of clinics and health care centers to
be sold on the black market than the liquid formulations
of levomethadone and methadone. However, the avail-
ability of each of these OST medicines on the black mar-
ket is probably also influenced by other factors such as
prescription rates and prices. Bell for example found that
diversion to the black market occurs in proportion to
the amount of OST medicine prescribed to be taken
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availability of heroin on the market [32].
Regarding the exploration of predictive factors, we
found a small effect linking older age to levomethadone
use. Differences in the distribution of gender between
OST medicines support evidence that males more com-
monly consume illegal opiates [33]. Males’ tendency for
non-compliant use of buprenorphine over methadone
and levomethadone could point to gender based prefer-
ences for different substances’ effects or differences in
prescription patterns for male and female patients.
Our hypothesis regarding the predictive effects of anx-
iety relief and sedation could not be confirmed. How-
ever, the exploratory analysis of reasons for use showed
influencing factors that allow for a differential charac-
terization of the three OST medicines. Avoiding with-
drawal symptoms was more strongly associated with
the consumption of methadone than buprenorphine.
In Germany, methadone for OST has been available
longer and is prescribed more extensively than bupre-
norphine. It also dulls and subdues emotions more than
buprenorphine [23,24]. This might lead to the perception
among opioid dependent patients that methadone is more
effective in relieving withdrawal than buprenorphine. To
further explore this hypothesis, one could compare non-
compliant OST medicine consumption with countries like
France, where OST is primarily conducted with buprenor-
phine [29]. This finding could also point towards too low
doses of methadone that result in patients increasing
doses as they only experience side effects rather than suffi-
cient withdrawal relief. Unfortunately, we cannot confirm
this hypothesis as no mean OST medicine doses were re-
corded. However, several literature reviews have shown
that higher doses of OST medicine are more effective than
lower doses in retaining opioid dependent patients in
treatment and in reducing concomitant drug and opioid
use [34-36]. Current research in Germany found that one-
fifth of patients in OST perceived their substitution dosage
as being too low [20]. Results of the PREMOS study re-
vealed that one third of patients received OST dosages
that were below the minimal maintenance dosage [37].
According to our results, modulating the effects of other
substances was more strongly associated with levometha-
done than methadone and buprenorphine consumption.
We also found concurring evidence that parallel con-
sumption of levomethadone and other substances occurs
more often than for methadone and significantly more
often than for buprenorphine. This evidence suggests that
opioid dependent patients not only believe levomethadone
to be better at modulating effects but also consume ac-
cording to this belief. Levomethadone use was also linked
to worst expectations for improving or brightening mood,
as compared to the other two OST medicines. To the best
of our knowledge, no evidence has been found that thedextrorotary form in racemic methadone could be respon-
sible for opposite effects. Therefore, future studies could
further investigate the differential pharmacological effects
and side effects of levomethadone and methadone as well
as the reputation these substances have among opioid de-
pendent patients according to their perceived effects. The
non-compliant use of OST medicines to improve mood
suggests that comorbid psychiatric conditions such as de-
pression are not being diagnosed and treated appropri-
ately. The COBRA and PREMOS studies similarly found
high rates of psychiatric disorders among opioid depen-
dent persons with proportionally low treatment for these
psychiatric disorders [38,39]. This calls for improvements
in diagnosing comorbid disorders, especially mood disor-
ders, and in treating patients with antidepressants and
psychotherapy when necessary.
In summary, we have found differential patterns of
non-compliant OST medicine use. The first main pat-
tern indicates that non-compliant levomethadone and
methadone use is characterized by more frequent paral-
lel consumption of other psychoactive substances and
intravenous use, whereas buprenorphine is more often
procured without a prescription. Second, reasons for use
differ between OST medicines in that methadone was
perceived to relieve withdrawal symptoms better than
buprenorphine, and levomethadone was perceived as be-
ing better at modulating the effects of other substances
and worst at enhancing mood. Our exploratory analysis
yields preliminary results on the factors that predict and
characterize non-compliant OST medicine use. How-
ever, moderators such as duration of addiction, past
treatment, current type and duration of treatment, aver-
age OST dose, comorbidity, and psychotropic drug use
are still to be explored in order to better understand
non-compliance to OST.
The study is limited by certain factors. First, we have
no information on the overall number of patients being
treated with each OST medicine or on patients’ OST
status (e.g. current and past prescriptions, duration of
treatment). This makes a calculation of the proportion
of non-compliant to compliant users as well as a calcula-
tion of rates of non-compliant use for the different OST
medicines unrealizable. Additional data would allow for
comparisons between groups, enable a country-wide es-
timate of non-compliance within OST, and clarify the in-
fluence of OST status on non-compliant OST medicine
use. Second, although patients are assumed to answer
honestly because of anonymous, voluntary participation
with no repercussions for treatment, we cannot com-
pletely discard the possibility of dishonest answers. Third,
given the explorative nature of this analysis, we deliber-
ately refrained from adjusting for multiple testing in order
to gain as much information as possible on differential
patterns of OST use. Future research could build on the
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search methods (e.g. examining the use of OST medicines
by comparing patients in and out of treatment) and by in-
corporating the above listed additional moderators. Fi-
nally, the first two characteristics of non-compliance are
relatively open. For the variable “parallel consumption of
OST medicine and other drugs”, no information is avail-
able on the type of drug used, frequency of use or its detri-
mental effects. For example, both harmful daily alcohol
use and occasional cannabis consumption could have ful-
filled this criterion. Further information on drug type
could help explain intended effect modulations. Addition-
ally, “use of OST medicine not as medically intended” is a
general characteristic that can encompass many different
types of use. We relied on the expertise of trained per-
sonnel when selecting these categories. The ambiguity of
these criteria increases sensitivity but also decreases speci-
ficity. Tightening these criteria could yield a more homo-
geneous group.
Conclusion
Non-compliance to OST remains a challenge in the
treatment of opioid dependent persons. The effects of
several moderators on compliance is still to be under-
stood. Our results raise a number of implications for
prevention, treatment and policy. First, reducing intra-
venous consumption of OST medicines and informing
consumers of risks related to intravenous use is crucial.
Along this note, the continued development of formula-
tions that deter intravenous use and additional investiga-
tions into the effects of product form on non-compliant
use are necessary to inform changes in the licensing and
dispensing of OST medicines. Second, maintenance dos-
ages need to be critically reviewed, especially for metha-
done. Increasing dosages among patients that are still
suffering from withdrawal symptoms is one important
way in which clinicians can contribute to patients’ OST
compliance. Finally, there are still improvements to be
made in diagnosing and treating comorbid psychiatric
disorders, especially mood disorders. This would be a
major contribution to improving quality of life among
opioid dependent persons and could help reduce the
non-compliant use of OST medicines as self-treatment
of psychiatric symptoms.
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